Monoclonal antibodies (mAbs) are well-established therapeutics, as evidenced by the large number of Food and Drug Administration-approved mAbs for the treatment of cancers, and inflammatory or autoimmune diseases, and for the prevention and treatment of solid organ transplant rejection. Although, in many cases, mAbs have improved patient survival, they are also associated with an increased incidence of opportunistic infections. We review here the current and next generation of mAbs and the risks that infectious disease specialists should be aware of.
MAGGI, FABRIZIO (Secondo)
|Autori:||Focosi, D; Maggi, F; Pistello, Mauro; Boggi, Ugo; Scatena, F.|
|Titolo:||Immunosuppressive monoclonal antibodies: current and next generation|
|Anno del prodotto:||2011|
|Digital Object Identifier (DOI):||10.1111/j.1469-0691.2011.03677.x|
|Appare nelle tipologie:||1.1 Articolo in rivista|